NasdaqCM - Nasdaq Real Time Price USD

Silexion Therapeutics Corp (SLXNW)

Compare
0.0900
+0.0020
+(2.27%)
As of 10:40:09 AM EST. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for SLXNW

Recent News: SLXNW

View More
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
GlobeNewswire yesterday
PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market
Business Wire 2 days ago
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
GlobeNewswire 3 days ago

PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments
Business Wire 14 days ago
Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering
GlobeNewswire 15 days ago
Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies
GlobeNewswire 15 days ago
Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium
GlobeNewswire 18 days ago
Silexion Therapeutics, Evonik collaborate on siRNA formulation development

Silexion Therapeutics, Evonik collaborate on siRNA formulation development
TipRanks last month
PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises
Business Wire last month
Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development

Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
GlobeNewswire last month
Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors

Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors
GlobeNewswire last month
View More

Related Tickers

SXTPW 60 Degrees Pharmaceuticals, Inc.
0.0350
+5.42%
 
OCEAW Ocean Biomedical, Inc.
0.0387
+17.99%
 
SXTP 60 Degrees Pharmaceuticals, Inc.
0.7521
-5.99%
 
ATHE Alterity Therapeutics Limited
4.2150
-7.79%
 
OCEA Ocean Biomedical, Inc.
0.2006
+5.87%
 
ABVC ABVC BioPharma, Inc.
0.5120
-2.40%
 
BDRX Biodexa Pharmaceuticals Plc
4.3450
+1.76%
 
TVGNW Tevogen Bio Holdings Inc.
0.0748
0.00%
 
PALI Palisade Bio, Inc.
1.3800
-3.50%
 
KZIA Kazia Therapeutics Limited
1.4702
-22.62%